×
About 126,602 results

ALLMedicine™ Hepatocellular Carcinoma Center

Research & Reviews  62,049 results

FDA Approval Summary: Nivolumab plus ipilimumab for the treatment of patients with hepa...
https://doi.org/10.1002/onco.13819
The Oncologist; Saung MT, Pelosof L et. al.

May 11th, 2021 - On March 10, 2020, the FDA granted accelerated approval to nivolumab in combination with ipilimumab for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib. The recommended approved dosage was nivolumab ...

A model selection framework to quantify microvascular liver function in gadoxetate-enha...
https://doi.org/10.1002/mrm.28798
Magnetic Resonance in Medicine; Berks M, Little RA et. al.

May 11th, 2021 - We introduce a novel, generalized tracer kinetic model selection framework to quantify microvascular characteristics of liver and tumor tissue in gadoxetate-enhanced dynamic contrast-enhanced MRI (DCE-MRI). Our framework includes a hierarchy of ne...

Surgical Outcome of Pulmonary Metastasectomy for Hepatocellular Carcinoma Recurrence in...
https://doi.org/10.12659/AOT.930383
Annals of Transplantation; Jeong YH, Hwang S et. al.

May 11th, 2021 - BACKGROUND Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) results in poor survival outcome. This study assessed the clinical outcomes of pulmonary metastasectomy in LT recipients with pulmonary metastasis of HCC in a...

see more →

Guidelines  147 results

Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis,...
https://doi.org/10.1016/j.clinre.2020.101590
Clinics and Research in Hepatology and Gastroenterology; Blanc JF, Debaillon-Vesque A et. al.

Mar 29th, 2021 - This document is a summary of the French Intergroup guidelines regarding the management of hepatocellular carcinoma (HCC) published in March 2019. It is a collaborative work under the auspices of most of the French medical societies involved in th...

Hepatocellular carcinoma
https://www.nature.com/articles/s41572-020-00240-3
Nature Reviews; Llovet JM

Jan 20th, 2021 - Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepa...

Diagnostic and Prognostic Implications of Cardiac Markers for Hepatocellular Carcinoma
https://pubmed.ncbi.nlm.nih.gov/33641280/
Critical Reviews in Oncogenesis; Ghanta MK

Jan 1st, 2021 - Hepatocellular carcinoma (HC) is a malignant primary liver cancer which has poor treatment outcomes in advanced stages, and many of the HC patients present with advanced stages. The incidence of death due to HC increase as a result of ineffective ...

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achie...
https://doi.org/10.1053/j.gastro.2020.11.051
Gastroenterology Younossi ZM, Corey KE et. al.

Dec 11th, 2020 - Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with global public health impact affecting more than 25% of the global population. NAFLD is associated with significant morbidity and mortality from cirrhosis, h...

Liver Cancer - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK448337/
StatPearls [Internet]; Recio-Boiles A

Nov 18th, 2020 - Hepatocellular carcinoma is the most common form of primary liver cancer in the United States with three-quarters of primary and secondary liver cancer cases. The trend for both estimated new and instances of death is increasing in parallel to the...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  63,205 results

FDA Approval Summary: Nivolumab plus ipilimumab for the treatment of patients with hepa...
https://doi.org/10.1002/onco.13819
The Oncologist; Saung MT, Pelosof L et. al.

May 11th, 2021 - On March 10, 2020, the FDA granted accelerated approval to nivolumab in combination with ipilimumab for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib. The recommended approved dosage was nivolumab ...

A model selection framework to quantify microvascular liver function in gadoxetate-enha...
https://doi.org/10.1002/mrm.28798
Magnetic Resonance in Medicine; Berks M, Little RA et. al.

May 11th, 2021 - We introduce a novel, generalized tracer kinetic model selection framework to quantify microvascular characteristics of liver and tumor tissue in gadoxetate-enhanced dynamic contrast-enhanced MRI (DCE-MRI). Our framework includes a hierarchy of ne...

Surgical Outcome of Pulmonary Metastasectomy for Hepatocellular Carcinoma Recurrence in...
https://doi.org/10.12659/AOT.930383
Annals of Transplantation; Jeong YH, Hwang S et. al.

May 11th, 2021 - BACKGROUND Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) results in poor survival outcome. This study assessed the clinical outcomes of pulmonary metastasectomy in LT recipients with pulmonary metastasis of HCC in a...

see more →

News  1,179 results

Antibiotics May Prolong PFS in HCC Patients on Immunotherapy
https://www.medscape.com/viewarticle/949665

Apr 20th, 2021 - Exposure to antibiotics 30 days before or after starting treatment with an immune checkpoint inhibitor (ICI) was associated with a benefit in progression-free survival (PFS) among patients with hepatocellular carcinoma (HCC) in an international st...

New Combo Shows Benefit Even in Patients With High-Risk HCC
https://www.medscape.com/viewarticle/949271

Apr 13th, 2021 - Updated data continue to show significant clinical benefits for patients with unresectable hepatocellular carcinoma (HCC) with the combination of the immune checkpoint inhibitor atezolizumab (Tecentriq) and angiogenesis inhibitor bevacizumab (Avas...

ASCO Announces New Advanced Liver Cancer Guidelines
https://www.medscape.com/viewarticle/946306

Feb 22nd, 2021 - New guidelines from the American Society of Clinical Oncology were released to address the treatment of advanced hepatocellular carcinoma (HCC). An unprecedented number of new agents have been approved for systemic therapy of HCC in recent years, ...

Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer
https://www.medscape.com/viewarticle/945046

Jan 31st, 2021 - Long-term follow-up data show a continued benefit for patients with advanced hepatocellular carcinoma (HCC) treated with nivolumab and ipilimumab after disease progression on sorafenib, according to investigators from the Checkmate 040 trial. At a...

TACTICS: TACE Plus Sorafenib Improves PFS in Unresectable HCC
https://www.medscape.com/viewarticle/945041

Jan 31st, 2021 - Combining transcatheter arterial chemoembolization (TACE) therapy with sorafenib improved progression-free survival (PFS), but not overall survival (OS), when compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC), f...

see more →

Patient Education  5 results see all →